Detalhe da pesquisa
1.
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(9): 989-1001, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591293
2.
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Cancer
; 129(14): 2256-2265, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37151113
3.
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(4): 465-478, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35298906
4.
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Lancet
; 397(10274): 592-604, 2021 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33581821
5.
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
Br J Cancer
; 121(5): 429-430, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31350526
6.
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
Br J Cancer
; 120(2): 183-189, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30531832
7.
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.
Lung Cancer
; 193: 107821, 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38820979
8.
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
J Thorac Oncol
; 18(6): 755-768, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37001859
9.
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Nat Med
; 28(11): 2374-2380, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36008722
10.
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Eur J Cancer
; 149: 222-232, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33872982
11.
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
J Natl Cancer Inst
; 113(8): 1005-1016, 2021 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33523233
12.
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.
J Clin Oncol
; 39(9): 966-977, 2021 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33197226
13.
Chicken embryos can maintain heart rate during hypoxia on day 4 of incubation.
J Comp Physiol B
; 190(3): 361-370, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32198537
14.
Physiological responses to acute changes in temperature and oxygenation in bird and reptile embryos.
Respir Physiol Neurobiol
; 178(1): 108-17, 2011 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-21513821
15.
Oxygen consumption as related to the development of the extraembryonic membranes and cardiovascular system in the European pond turtle (Emys orbicularis) embryogenesis.
Comp Biochem Physiol A Mol Integr Physiol
; 148(3): 599-610, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17869562
16.
Physiological and morphological characteristics of the rhythmic contractions of the amnion in veiled chameleon (Chamaeleo calyptratus) embryogenesis.
Comp Biochem Physiol A Mol Integr Physiol
; 140(1): 19-28, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15664309
17.
Rhythmic contractions in chick amnio-yolk sac and snake amnion during embryogenesis.
Comp Biochem Physiol A Mol Integr Physiol
; 131(4): 861-70, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-11897197